Robert F. Kennedy Jr. appointed advisers vote to allow compounding pharmacies to produce four unapproved peptides.
The Food and Drug Administration’s Pharmacy Compounding Advisory Committee voted to allow compounding pharmacies to produce four unapproved peptides, moving them toward a more regulated status. The committee members, many of whom were appointed under Health Secretary Robert F. Kennedy Jr., voted in favor of BPC-157, KPV, and TB-500, with a majority also supporting MOTS-c. While the wellness industry championed the move to provide patients with more options, agency scientists expressed concern over a lack of definitive chemical formulas and clinical data. Proponents, including Robert F. Kennedy Jr., argued that allowing these peptides to be compounded would move consumers away from the "gray market," where products are often sold without official oversight. Conversely, some medical experts warned that the decision might be driven by market demand rather than solid science. The committee's recommendation does not constitute final FDA approval, but it signals a shift toward greater medical freedom for patients seeking benefits like improved sleep, faster healing, and anti-aging effects.